ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a significant growth in short interest in February. As of February 15th, there was short interest totalling 4,420,000 shares, a growth of 5,106.1% from the January 31st total of 84,900 shares. Based on an average daily volume of 8,590,000 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Trading of ProPhase Labs

Large investors have recently made changes to their positions in the stock. SVB Wealth LLC bought a new stake in shares of ProPhase Labs during the 4th quarter worth about $36,000. Squarepoint Ops LLC bought a new stake in shares of ProPhase Labs during the 4th quarter worth about $40,000. Warberg Asset Management LLC bought a new stake in shares of ProPhase Labs during the 4th quarter worth about $77,000. Geode Capital Management LLC boosted its stake in shares of ProPhase Labs by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after acquiring an additional 13,590 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in shares of ProPhase Labs by 18.3% during the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after acquiring an additional 27,673 shares in the last quarter. Institutional investors own 9.45% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on ProPhase Labs in a research note on Tuesday. They issued a “sell” rating on the stock.

ProPhase Labs Stock Performance

Shares of NASDAQ PRPH opened at $0.45 on Friday. The business’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $1.41. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. ProPhase Labs has a one year low of $0.22 and a one year high of $7.48. The company has a market capitalization of $10.71 million, a P/E ratio of -0.36 and a beta of -0.37.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.